Combination treatment for generalized myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new combination treatment for generalized myasthenia gravis. It combines two medications to help reduce muscle weakness and improve your daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have a diagnosis of generalized myasthenia gravis with a positive AChR antibody test result.
- Your symptoms are moderate to severe, like drooping eyelids, double vision, or trouble swallowing, based on a symptom score.
- You are not pregnant or breastfeeding, and you agree to use contraception if needed.
- You do not have other active autoimmune diseases, active infections (like HIV or tuberculosis), or significant liver/kidney problems.
- You have not had certain biologic treatments recently (like rituximab within 6 months or IVIg within 2 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests a new drug called telitacicept combined with low-dose steroids for people with myasthenia gravis that hasn't improved with standard treatments. It aims to reduce muscle weakness and improve daily function.
This study adds a new drug called empasiprubart to the existing treatment efgartigimod for people with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChR-Ab) and have only partially responded to efgartigimod. The goal is to see if the combination improves daily living more than efgartigimod alone.
This study tests whether continuing efgartigimod after a myasthenia gravis crisis helps keep symptoms under control and prevent future flare-ups. It is for people who have already responded to one round of this treatment.
This trial tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis (gMG). If you have gMG with certain antibodies and current treatments aren't working well enough, this study may help find a better option.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.